Autres langues Corvus Pharmaceuticals, Inc.

Actions

CRVS

US2210151005

Temps Différé Nasdaq Autres places de cotation 18:58:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
1,529 ^USD	+5,46%		+6,19%	-13,12%

09/04	Corvus Pharmaceuticals, Inc. annonce le lancement d'un essai clinique de phase 1 contrôlé par placebo sur le soquelitinib dans le traitement de la dermatite atopique	CI
21/03	CORVUS PHARMACEUTICALS, INC. : Oppenheimer à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20/03
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	19/03
Corvus: Q4 Earnings Snapshot	19/03
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	13/03
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Sector Update: Health Care Stocks Mixed in Afternoon Trading	09/02
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	09/02
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	09/02
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	08/02
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	08/02
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	06/02
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	06/02
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	23/01
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors	23/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Corvus Pharmaceuticals, Inc.

Actions

CRVS

US2210151005

Autres langues

Filtres